Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis.

Autor: Grempler R; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma Inc, 900 Ridgebury Road, Ridgefield, CT, 06877, USA. rolf.grempler@boehringer-ingelheim.com., Ahlberg J; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Germovsek E; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim am Rhein, Germany., Gupta P; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Li H; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Pilvankar M; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Sharma A; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma Inc, 900 Ridgebury Road, Ridgefield, CT, 06877, USA., Stopfer P; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an der Riss, Germany., Hansel S; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Jan; Vol. 41 (1), pp. 364-378. Date of Electronic Publication: 2023 Nov 16.
DOI: 10.1007/s12325-023-02710-y
Abstrakt: Introduction: Accurate predictions of pharmacokinetics and efficacious doses for biologics in humans are critical for selecting appropriate first-in-human starting doses and dose ranges and for estimating clinical material needs and cost of goods. This also impacts clinical feasibility, particularly for subcutaneously administered biologics.
Methods: We performed a comprehensive comparison between predicted and observed clearances and doses in humans for a set of 22 biologic drugs developed at Boehringer Ingelheim (BI) over the last 2 decades. The analysis included biologics across three therapeutic areas comprising a wide variety of modalities: mono- and bispecific monoclonal antibodies (mAbs) and nanobodies and a Fab fragment.
Results: Our analysis showed that observed clearances in humans were within twofold of predicted clearances for 17 out of 20 biologics (85%). Six biologics had uncharacteristically high observed human clearances (range 32-280 mL/h) for their respective molecular classes, impacting their clinical developability. For three molecules, molecular characteristics contributed to the high clearance. Clinically selected doses were within twofold of predicted for 58% of projects. With 42% and 25% of projects selecting clinical doses higher than two- or threefold the predicted value, respectively, the importance of better understanding not only the pharmacokinetic (PK) but also the predictivity of pharmacodynamic models is highlighted.
Conclusions: We provide a clinical pharmacology perspective on the commonly accepted twofold range of human clearance predictions as well as the implications of higher than predicted targeted efficacious plasma concentration on clinical development. Finally, an analysis of key success factors for biologics at BI was conducted, which may be relevant for the entire pharmaceutical industry. This is one of the largest retrospective analyses for biologics and provides further evidence that successful predictions of human PK and efficacious dose will be further facilitated by gathering key translational data early in research.
(© 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: